Assessment of efficacy and safety of immunotherapy for unresectable locally advanced pancreatic cancer.

Assessment of efficacy and safety of immunotherapy for unresectable locally advanced pancreatic cancer. - Immunotherapy for pancreatic cancer.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000769

Enrollment

Registered

2007-09-01

Start date

2007-08-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic ductal carcinoma

Interventions

Endoscopic therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: Patients with immunologic abnormalities

Design outcomes

Primary

Measure	Time frame
OS	—

Countries

Japan

Contacts

Public ContactYoshiki Hirooka

Nagoya University Hospital Department of Endoscopy

hirooka@med.nagoya-u.ac.jp052-744-2602

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026